The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -11,431 |
| Bad debt (recovery) expense | -211 |
| Amortization of debt discount | 466 |
| Amortization of acquired intangible assets | 4,258 |
| Amortization of operating lease right-of-use assets | 88 |
| Share-based compensation | 6,288 |
| Accounts receivable | 19,341 |
| Inventory | -4,807 |
| Prepaid expenses and other current assets | 164 |
| Accounts payable | -7,199 |
| Related party expenses | -73 |
| Accrued expenses | 10,149 |
| Accrued interest | -6 |
| Income tax payable | 10 |
| Lease liabilities | -82 |
| Net cash (used in) operating activities | -12,441 |
| Proceeds from the exercise of stock options | 350 |
| Proceeds from issuance of common stock, atm offering, net of issuance costs | 16,359 |
| Issuance of common stock under espp | 217 |
| Payment of debt issuance costs | 75 |
| Payment of license installment note payable | 625 |
| Net cash provided by financing activities | 16,226 |
| Net change in cash | 3,785 |
| Cash at the beginning of the period | 20,305 |
| Cash at the end of the period | 24,090 |
Journey Medical Corp (DERM)
Journey Medical Corp (DERM)